Physician profile
Danara Nelson
NPI 1588115430
$3,764.58
in general payments reported to CMS, 2019-2025
15 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $456 · 2022: $844 · 2023: $1,313 · 2024: $1,008 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,464.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $960.84 | 2021-2024 | Austedo Xr, Austedo, Uzedy |
| Otsuka America Pharmaceutical, INC. | $566.79 | 2021-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $484.55 | 2021-2025 | Vivitrol, Vivitrol |
| Abbvie INC. | $404.78 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $392.47 | 2022-2025 | Invega Sustenna, Spravato |
| Gilead Sciences, INC. | $161.12 | 2023-2024 | Epclusa |
| Axsome Therapeutics, INC. | $146.07 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $123.98 | 2024 | Fanapt |
| Neurocrine Biosciences, INC. | $116.66 | 2023 | Ingrezza |
| Livanova USA, INC. | $112.46 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.41 | 2022 | |
| Uswm, LLC | $81.46 | 2024 | Lucemyra |
| Indivior INC. | $47.61 | 2022-2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $44.63 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.75 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danara Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.